Patents by Inventor Marilyn H. Perrin
Marilyn H. Perrin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6953838Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2? or ?. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.Type: GrantFiled: February 3, 2004Date of Patent: October 11, 2005Assignee: Research Development FoundationInventors: Wylie W. Vale, Jr., Jean E. Rivier, Koichi S. Kunitake, Kathy A. Lewis, Marilyn H. Perrin, Jozsef Gulyas
-
Patent number: 6838274Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituituary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn II. Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: GrantFiled: July 31, 2001Date of Patent: January 4, 2005Assignee: Research Development FoundationInventors: Wylie W. Vale, Jr., Teresa M. Reyes, Paul E. Sawchenko, Jean E. Rivier, Kathy A. Lewis, John B. Hogenesch, Joan M. Vaughan, Marilyn H. Perrin
-
Patent number: 6812210Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2&agr; or &bgr;. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.Type: GrantFiled: March 15, 2002Date of Patent: November 2, 2004Assignee: Research Development FoundationInventors: Wylie W. Vale, Jr., Jean E. River, Koichi S. Kunitake, Kathy A. Lewis, Marilyn H. Perrin, Jozsef Gulyas
-
Publication number: 20040204564Abstract: CRF peptide analogs that bind to CRFR1 with an affinity far greater than they bind to CRFR2. These analogs exhibit CRF agonist activity.Type: ApplicationFiled: January 22, 2004Publication date: October 14, 2004Inventors: Jean E.F. Rivier, Wylie W. Vale, Marilyn H. Perrin, Jozsef Gulyas
-
Publication number: 20040143095Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2&agr; or &bgr;. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.Type: ApplicationFiled: February 3, 2004Publication date: July 22, 2004Applicant: Research Development FoundationInventors: Wylie W. Vale, Jean E. Rivier, Koichi S. Kunitake, Kathy A. Lewis, Marilyn H. Perrin, Jozsef Gulyas
-
Publication number: 20040039173Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of £ 10 nM of CRF occupy 350% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. Invention CRF-Rs can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.Type: ApplicationFiled: August 26, 2003Publication date: February 26, 2004Applicant: The Salk Institute for Biological StudiesInventors: Marilyn H. Perrin, Ruoping Chen, Kathy A. Lewis, Wylie W. Vale, Cynthia J. Donaldson, Paul Sawchenko
-
Patent number: 6638905Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of 10 nM of CRF occupy 50% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. Invention CRF-Rs can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.Type: GrantFiled: November 12, 1998Date of Patent: October 28, 2003Assignee: The Salk Institute for Biological StudiesInventors: Marilyn H. Perrin, Ruoping Chen, Kathy A. Lewis, Wylie W. Vale, Jr., Cynthia J. Donaldson, Paul Sawchenko
-
Publication number: 20030036507Abstract: A search of the public human genome database identified a human EST, GenBank accession number AW293249, which has high homology to known pufferfish urocortin sequences. The full length sequence was amplified from human genomic DNA and sequenced. Sequence homology comparisons of the novel sequence with human urocortin I and urocortin II revealed that the sequence encoded a novel human urocortin, which was designated urocortin III (UcnIII). While urocortin III does not have high affinity for either CRF-R1 or CRF-R2, the affinity for CRF-R2 is greater than the affinity for CRF-R1. Urocortin III is capable stimulating cyclic AMP production in cells expressing CRF-R2&agr; or &bgr;. Thus, the affinity is high enough that urocortin III could act as a native agonist of CRF-R2. However, it is also likely that urocortin III is a stronger agonist of a yet to be identified receptor.Type: ApplicationFiled: March 15, 2002Publication date: February 20, 2003Inventors: Wylie W. Vale, Kathy A. Lewis, Marilyn H. Perrin, Koichi S. Kunitake, Jozsef Gulyas, Jean E. Rivier
-
Publication number: 20030032587Abstract: Urocortin (Ucn) is a native mammalian peptide generally related to Urotensin I and Corticotropin Releasing Factor (CRF). Human Ucn has the formula: Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2 (SEQ ID NO: 15). Rat-derived Ucn is identical but for 2 substitutions, Asp2 for Asn2 and Pro4 for Ser4. Ucn or analogs thereof or pharmaceutically acceptable salts can be administered to humans and other mammals to achieve substantial elevation of ACTH, &bgr;-endorphin, &bgr;-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone. They can also be used to lower blood pressure over an extended period of time, as stimulants to elevate mood and to improve memory and learning performance, as well as diagnostically. Shortened fragments may be administered to release endogenous CRF and/or Ucn in the brain and peripherally.Type: ApplicationFiled: March 26, 2001Publication date: February 13, 2003Applicant: The Salk Institute for Biological StudiesInventors: Wylie W. Vale, Joan Vaughan, Cynthia J. Donaldson, Kathy A. Lewis, Paul Sawchenko, Jean E.F. Rivier, Marilyn H. Perrin
-
Patent number: 6495343Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of ≦10 nM of CRF occupy ≧50% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. Invention CRF-Rs can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.Type: GrantFiled: January 17, 1995Date of Patent: December 17, 2002Assignee: The Salk Institute for Biological StudiesInventors: Marilyn H. Perrin, Ruoping Chen, Kathy A. Lewis, Wylie W. Vale, Jr., Cynthia J. Donaldson, Paul Sawchenko
-
Patent number: 6482608Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of 10 nM of CRF occupy 50% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. Invention CRF-Rs can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.Type: GrantFiled: May 26, 2000Date of Patent: November 19, 2002Assignee: The Salk Institute for Biological StudiesInventors: Marilyn H. Perrin, Ruoping Chen, Kathy A. Lewis, Wylie W. Vale, Jr., Cynthia J. Donaldson, Paul Sawchenko
-
Publication number: 20020127221Abstract: A human urocortin-related peptide with significant sequence homology to the CRF neuropeptide family was identified. A mouse cDNA was isolated from whole brain poly (A+) RNA that encodes a predicted 38 amino acid peptide protein designated herein as urocortin II. Both human URP and mouse Ucn II are structurally related to the other known mammalian family members, CRF and urocortin (Ucn). These peptides are involved in the regulation of the hypothalamic-pituitary-adrenal axis under basal and stress conditions, suggesting a similar role for URP and Ucn II. Synthesized Ucn-II and URP peptide binds with higher affinity to CRF-R2 than to CRF-R1 Ucn II and human URP appear to be involved in the regulation of body temperature and appetite and may play a role in other stress related phenomenon. These findings identify Ucn II and human URP as a new members of the CRF family of neuropeptides, which are expressed centrally and bind to CRF-R2.Type: ApplicationFiled: July 31, 2001Publication date: September 12, 2002Inventors: Wylie W. Vale, Teresa M. Reyes, Paul E. Sawchenko, Jean E. Rivier, Kathy A. Lewis, John B. Hogenesch, Joan M. Vaughan, Marilyn H. Perrin
-
Patent number: 6399315Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of ≦10 nM of CRF occupy ≧50% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. Invention CRF-Rs can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.Type: GrantFiled: June 7, 1995Date of Patent: June 4, 2002Assignee: The Salk Institute for Biological StudiesInventors: Marilyn H. Perrin, Ruoping Chen, Kathy A. Lewis, Wylie W. Vale, Jr., Cynthia J. Donaldson, Paul Sawchenko
-
Publication number: 20020055617Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of £ 10 nM of CRF occupy 50% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. Invention CRF-Rs can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.Type: ApplicationFiled: November 12, 1998Publication date: May 9, 2002Inventors: MARILYN H. PERRIN, RUOPING CHEN, KATHY A. LEWIS, WYLIE W. VALE, CYNTHIA J. DONALDSON, PAUL SAWCHENKO
-
Patent number: 6214797Abstract: Urocortin (Ucn) is a native mammalian peptide generally related to Urotensin I and Corticotropin Releasing Factor (CRF). Human Ucn has the formula: Asp-Asn-Pro-Ser-Leu-Ser-Ile-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Thr-Leu-Leu-Glu-Leu-Ala-Arg-Thr-Gln-Ser-Gln-Arg-Glu-Arg-Ala-Glu-Gln-Asn-Arg-Ile-Ile-Phe-Asp-Ser-Val-NH2 (SEQ ID NO:15). Rat-derived Ucn is identical but for 2 substitutions, Asp2 for Asn2 and Pro4 for Ser4. Ucn or analogs thereof or pharmaceutically acceptable salts can be administered to humans and other mammals to achieve substantial elevation of ACTH, &bgr;-endorphin, &bgr;-lipotropin, other products of the pro-opiomelanocortin gene and corticosterone. They can also be used to lower blood pressure over an extended period of time, as stimulants to elevate mood and to improve memory and learning performance, as well as diagnostically. Shortened fragments may be administered to release endogenous CRF and/or Ucn in the brain and peripherally.Type: GrantFiled: December 10, 1997Date of Patent: April 10, 2001Assignee: The Salk Institute for Biological StudiesInventors: Wylie W. Vale, Jr., Joan Vaughan, Cynthia J. Donaldson, Kathy A. Lewis, Paul Sawchenko, Jean E. F. Rivier, Marilyn H. Perrin
-
Patent number: 5728545Abstract: In accordance with the present invention, there are provided novel G-protein-coupled receptor proteins (CRF-R) characterized by having sufficient binding affinity for corticotropin releasing factor (CRF) such that concentrations of .ltoreq.10 nM of CRF occupy .gtoreq.50% of the binding sites of said receptor protein. Nucleic acid sequences encoding such receptors, assays employing same, as well as antibodies derived therefrom, are also disclosed. The invention CRF-R can be employed in a variety of ways, such as, for example, in bioassays, for production of antibodies thereto, in therapeutic compositions containing such proteins and/or antibodies.Type: GrantFiled: August 23, 1993Date of Patent: March 17, 1998Assignee: The Salk Institute of Biological StudiesInventors: Marilyn H. Perrin, Ruoping Chen, Kathy A. Lewis, Wylie W. Vale, Jr., Cynthia J. Donaldson
-
Patent number: 4661472Abstract: Peptides which inhibit the secretion of gonadotropins by the pituitary gland and inhibit the release of steroids by the gonads. Administration of an effective amount of such GnRH antagonists prevents ovulation of female mammalian eggs and/or the release of steroids by the gonads. These peptides may be used to treat steroid-dependent tumors, such as prostatic and mammary tumors. The peptides are cyclic analogs of the decapeptide GnRH wherein there is a covalent bond between the residue in the 4-position and the residue in the 10-position. Examples of such bonds include the disulfide linkage between Cys residues, an amide linkage between a side chain amino group and a side chain carboxyl group, a dicarba linkage between side-chain alkyl groups, and a carba linkage between a side-chain alkyl group and a side-chain sulfhydryl group.Type: GrantFiled: May 9, 1985Date of Patent: April 28, 1987Assignee: The Salk Institute for Biological StudiesInventors: Jean E. F. Rivier, Janos I. Varga, Arnold T. Hagler, R. Scott Struthers, Marilyn H. Perrin, Catherine L. Rivier, Wylie W. Vale, Jr.